AFFILIATIONS
1 Dana-Farber/Boston Children’s Cancer and Blood Disorders Center; Harvard Medical School, Boston, Massachusetts, United States
2 Dana-Farber/Boston Children’s Cancer and Blood Disorders Center; Harvard Medical School, Boston, Massachusetts, United States
3 Dana-Farber/Boston Children’s Cancer and Blood Disorders Center; Harvard Medical School, Boston, Massachusetts, United States
4 Dana-Farber/Boston Children’s Cancer and Blood Disorders Center; Harvard Medical School, Boston, Massachusetts, United States
5 Dana-Farber/Boston Children’s Cancer and Blood Disorders Center; Harvard Medical School, Boston, Massachusetts, United States
6 Dana-Farber/Boston Children’s Cancer and Blood Disorders Center; Harvard Medical School, Boston, Massachusetts, United States
7 Dana-Farber/Boston Children’s Cancer and Blood Disorders Center; Harvard Medical School, Boston, Massachusetts, United States
8 Massachusetts General Hospital, Charlestown, Massachusetts, United States
9 Dana-Farber/Boston Children’s Cancer and Blood Disorders Center; Harvard Medical School, Boston, Massachusetts, United States
10 Dana-Farber/Boston Children’s Cancer and Blood Disorders Center; Harvard Medical School, Boston, Massachusetts, United States
11 Tonix Pharmaceuticals Holding Corp, Berkeley Heights, New Jersey, United States
12 Tonix Pharmaceuticals Holding Corp, Berkeley Heights, New Jersey, United States
13 Massachusetts General Hospital, Charlestown, Massachusetts, United States
14 Tonix Pharmaceuticals Holding Corp, Berkeley Heights, New Jersey, United States
15 Dana-Farber/Boston Children’s Cancer and Blood Disorders Center; Harvard Medical School, Boston, Massachusetts, United States
ABSTRACT
Introduction: Despite advances in graft-versus-host disease (GVHD) prevention, infectious complications and delayed immune reconstitution remain common, highlighting the need for more selective prophylaxis approaches. Targeting the CD154-CD40 costimulatory pathway has demonstrated efficacy and tolerance-induction in preclinical models, however, early anti-CD154 antibodies caused thromboembolic complications through FcγRIIa-mediated platelet activation. TNX-1500 is a third-generation humanized IgG4 anti-CD154 monoclonal antibody engineered to minimize FcγRIIa binding while preserving CD154 blockade. Here, we evaluated whether TNX-1500 (TNX) combined with tacrolimus (Tac) could prevent severe acute GVHD in a rhesus macaque model of haploidentical HSCT.
Methods: Rhesus macaques (RMs) underwent G-CSF-mobilized peripheral blood stem cell haploidentical HSCT following myeloablative total body irradiation. Animals received no GVHD prophylaxis (‘NoRx’, n=11), TNX monotherapy (n=4), TNX/Tac (n=5), or Tac plus short-course methotrexate (Tac/MTX, n=3). TNX-1500 was administered at 30 mg/kg on days -1, +2, +7, and +14, followed by weekly dosing at 20 mg/kg through day +100. Tacrolimus was initiated on day -6 and maintained at a target trough concentration of 5–10 ng/mL through Day +100. Donor chimerism, GVHD, and immune reconstitution were assessed as previously described (Tkachev et al. Sci Transl Med. 2021). The primary endpoint was severe GVHD-free survival, defined as time from transplantation to euthanasia for severe acute GVHD; animals euthanized for other causes or surviving to study completion were censored.
Results: TNX-1500 was well tolerated, without infusion-related toxicity or renal or hepatic injury. Cytomegalovirus reactivation occurred in all TNX/Tac recipients but resolved with antiviral therapy without end-organ disease. Lymphocryptovirus (LCV; the rhesus equivalent of Epstein-Barr Virus) reactivated in three of five animals without post-transplant lymphoproliferative disease. LCV reactivation was prevented when rituximab was given as a single prophylactic dose prior to transplant.
All TNX/Tac recipients achieved donor engraftment, with median d+60 T-cell donor chimerism of 95.1% (range 90.5-100%). Median neutrophil and platelet engraftment occurred on days +13 and +30, respectively. TNX/Tac significantly prolonged severe GVHD-free survival (overall log-rank P<0.0001); median survival not reached for TNX/Tac versus 49 days with Tac/MTX, 13 days with TNX monotherapy, and 8 days for NoRx recipients. One TNX/Tac animal was censored for a catheter complication unrelated to GVHD on day +63. Another TNX/Tac animal developed no other signs of acute GVHD but was euthanized on day +77 for weight loss with suspected upper GI GVHD.
Total CD4+ and CD8+ T-cell reconstitution was comparable between groups at day +28, with no significant differences in total CD4+ or CD8+ T-cell frequencies or absolute counts. Compared with Tac/MTX, on Day +28, TNX/Tac recipients demonstrated higher frequencies of CD4+ naïve T cells (36.1% vs. 24.9%, P=0.036) and CD8+ naïve T cells (50.6% vs. 14.3%, P=0.036), accompanied by lower frequencies of CD4+ central memory T cells (36.2% vs. 59.1%, P=0.036). At Day +28, in TNX/Tac versus Tac/MTX recipients, the frequencies of CD8+ central memory T cells were 6.0% versus 22.5% (P=0.071), CD8+ effector memory T cells were similar between groups (16.6% for TNX/Tac versus 33.0% for Tac/MTX (P=0.14), and CD4+ effector memory T cells were 19.9% for TNX/Tac versus 24.7% for Tac/MTX (P=0.79). Treg frequencies were similar between groups at day +28 (TNX/Tac, 4.78% versus; Tac/MTX, 4.03%, P=0.79). These findings are consistent with the expected immunologic effects of CD154-CD40 costimulatory blockade, characterized by preservation of naïve T-cell populations and reduced central memory differentiation. The absence of differences in Treg frequencies may reflect concomitant tacrolimus therapy given previous work with CD154 blockade, either as a monotherapy, or when combined with sirolimus, which has demonstrated augmented Treg reconstitution.
Conclusions: TNX-1500 combined with tacrolimus was well tolerated, supported durable donor engraftment, and significantly prolonged severe GVHD-free survival while demonstrating enhanced naïve T cell reconstitution. These findings provide preclinical support for continued clinical development of TNX-1500.
DISCLOSURES
Lev Gorfinkel, MD: No relevant conflicts of interest to declare.